NO986209D0 - Ikke-vandige protiske peptidformuleringer - Google Patents

Ikke-vandige protiske peptidformuleringer

Info

Publication number
NO986209D0
NO986209D0 NO986209A NO986209A NO986209D0 NO 986209 D0 NO986209 D0 NO 986209D0 NO 986209 A NO986209 A NO 986209A NO 986209 A NO986209 A NO 986209A NO 986209 D0 NO986209 D0 NO 986209D0
Authority
NO
Norway
Prior art keywords
peptide formulations
aqueous protic
protic peptide
aqueous
formulations
Prior art date
Application number
NO986209A
Other languages
English (en)
Other versions
NO323933B1 (no
NO986209L (no
Inventor
James B Eckenhoff
Cynthia L Stevenson
Sally Tao
Steven J Prestrelski
Jeremy C Wright
Joe Leonard
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO986209D0 publication Critical patent/NO986209D0/no
Publication of NO986209L publication Critical patent/NO986209L/no
Publication of NO323933B1 publication Critical patent/NO323933B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NO19986209A 1996-07-03 1998-12-30 Stabil ikke-vandig formulering av en peptidforbindelse, fremgangsmate for fremstilling av denne og anvendelse av formuleringen til fremstillig av medikament. NO323933B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2112996P 1996-07-03 1996-07-03
PCT/US1997/010815 WO1998000152A1 (en) 1996-07-03 1997-07-01 Non-aqueous protic peptide formulations

Publications (3)

Publication Number Publication Date
NO986209D0 true NO986209D0 (no) 1998-12-30
NO986209L NO986209L (no) 1998-12-30
NO323933B1 NO323933B1 (no) 2007-07-23

Family

ID=21802501

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19986209A NO323933B1 (no) 1996-07-03 1998-12-30 Stabil ikke-vandig formulering av en peptidforbindelse, fremgangsmate for fremstilling av denne og anvendelse av formuleringen til fremstillig av medikament.

Country Status (27)

Country Link
EP (1) EP0909175B1 (no)
JP (3) JP2001504802A (no)
CN (1) CN1231256C (no)
AR (1) AR008060A1 (no)
AT (1) ATE241997T1 (no)
AU (1) AU737664B2 (no)
BR (1) BR9710130A (no)
CA (1) CA2259403A1 (no)
CO (1) CO4890854A1 (no)
CZ (1) CZ433898A3 (no)
DE (1) DE69722620T2 (no)
DK (1) DK0909175T3 (no)
ES (1) ES2201306T3 (no)
HU (1) HUP9903942A3 (no)
ID (1) ID19165A (no)
IL (1) IL127769A (no)
MY (1) MY121684A (no)
NO (1) NO323933B1 (no)
NZ (1) NZ333580A (no)
PL (1) PL189402B1 (no)
PT (1) PT909175E (no)
RO (1) RO119862B1 (no)
RU (1) RU2203085C2 (no)
SK (1) SK284490B6 (no)
TW (1) TW491703B (no)
WO (1) WO1998000152A1 (no)
ZA (1) ZA975942B (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2203085C2 (ru) * 1996-07-03 2003-04-27 Элзэ Копэрейшн Стабильный неводный препарат пептидного соединения, способ его получения и способ лечения гормон-зависимого заболевания у субъекта
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
AU2002316811A1 (en) 2001-06-28 2003-03-03 Novo Nordisk A/S Stable formulation of modified glp-1
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004031011D1 (de) * 2003-04-25 2011-02-24 Boston Scient Scimed Inc Feste arzneimittelformulierung und vorrichtung zu ihrer aufbewahrung und kontrollierten abgabe
TR201906789T4 (tr) * 2003-11-20 2019-05-21 Novo Nordisk As Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
CN101678112B (zh) * 2007-01-19 2016-08-31 哈南亚有限公司 用于递送治疗剂的方法和组合物
AU2013203271B2 (en) * 2007-01-19 2016-05-12 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
CA2730760A1 (en) 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
CN117530912A (zh) 2008-08-15 2024-02-09 硬木药品公司 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂
EP2376522A4 (en) 2008-11-16 2013-12-25 Univ Texas LOW VISCOSIS HIGHLY CONCENTRATED SUSPENSIONS
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
US8933030B2 (en) 2010-02-17 2015-01-13 Ironwwod Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
DK2603232T3 (da) 2010-08-11 2019-12-09 Ironwood Pharmaceuticals Inc Stabile formuleringer af linaclotid
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9708371B2 (en) 2011-08-17 2017-07-18 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
JP2013231030A (ja) * 2012-04-30 2013-11-14 Sun Pharmaceutical Industries Ltd リュープロリド注射剤
US9956287B2 (en) 2013-02-06 2018-05-01 Perosphere Inc. Stable glucagon formulations
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
EP3372224A1 (en) 2017-03-07 2018-09-12 Alrise Biosystems GmbH New controlled drug delivery system using water miscible solvents for production of drug loaded micro- and nanoparticles
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897256A (en) * 1986-11-25 1990-01-30 Abbott Laboratories LHRH analog formulations
ATE99543T1 (de) * 1987-10-15 1994-01-15 Syntex Inc Pulverfoermige zubereitungen zur intranasalen verabreichung von polypeptiden.
US4980163A (en) * 1989-03-01 1990-12-25 Public Health Research Institute Of The City Of New York Novel bacteriocin compositions for use as enhanced broad range bactericides and methods of preventing and treating microbial infection
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
IT1237197B (it) * 1989-11-16 1993-05-26 Sclavo Spa Formulazioni farmaceutiche anidre e forme di dosaggio per la somministrazione rettale di calcitonina.
RU2008354C1 (ru) * 1991-03-13 1994-02-28 Данилевич Василий Николаевич Способ хранения препарата протеиназ
ES2107051T3 (es) * 1992-09-21 1997-11-16 Upjohn Co Formulaciones de proteinas de liberacion sostenida.
DE69426292T2 (de) * 1993-02-23 2001-05-17 Genentech, Inc. Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff
US5955430A (en) * 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
JP3597233B2 (ja) * 1993-10-21 2004-12-02 久光製薬株式会社 経鼻組成物及びそれを含有する経鼻製剤
RU2203085C2 (ru) * 1996-07-03 2003-04-27 Элзэ Копэрейшн Стабильный неводный препарат пептидного соединения, способ его получения и способ лечения гормон-зависимого заболевания у субъекта

Also Published As

Publication number Publication date
MY121684A (en) 2006-02-28
JP2001504802A (ja) 2001-04-10
NZ333580A (en) 2000-06-23
CO4890854A1 (es) 2000-02-28
DK0909175T3 (da) 2003-09-29
PL330869A1 (en) 1999-06-07
AR008060A1 (es) 1999-12-09
ZA975942B (en) 1998-04-16
IL127769A0 (en) 1999-10-28
AU737664B2 (en) 2001-08-30
TW491703B (en) 2002-06-21
ID19165A (id) 1998-06-28
EP0909175A1 (en) 1999-04-21
CN1224356A (zh) 1999-07-28
SK179998A3 (en) 1999-05-07
PL189402B1 (pl) 2005-08-31
CN1231256C (zh) 2005-12-14
RU2203085C2 (ru) 2003-04-27
DE69722620T2 (de) 2004-04-29
EP0909175B1 (en) 2003-06-04
BR9710130A (pt) 1999-08-10
NO323933B1 (no) 2007-07-23
PT909175E (pt) 2003-10-31
HUP9903942A2 (hu) 2000-04-28
WO1998000152A1 (en) 1998-01-08
NO986209L (no) 1998-12-30
IL127769A (en) 2006-10-31
CA2259403A1 (en) 1998-01-08
JP2010043105A (ja) 2010-02-25
ES2201306T3 (es) 2004-03-16
RO119862B1 (ro) 2005-05-30
CZ433898A3 (cs) 1999-04-14
SK284490B6 (sk) 2005-05-05
DE69722620D1 (de) 2003-07-10
AU3407397A (en) 1998-01-21
HUP9903942A3 (en) 2000-07-28
JP2008195739A (ja) 2008-08-28
ATE241997T1 (de) 2003-06-15

Similar Documents

Publication Publication Date Title
NO986209D0 (no) Ikke-vandige protiske peptidformuleringer
NO986207L (no) Ikke-vandige polare aprotiske peptidformuleringer
NO986208L (no) Vandige peptidformuleringer
NO982519D0 (no) Formet ladning
MA24473A1 (fr) Formulations
DE59702237D1 (de) Abtrennvorrichtung
NO985680L (no) Peptidderivater
DE59708688D1 (de) Trennschalter
DE59711825D1 (de) Leistungsschalter
NO983849D0 (no) Peptidderivater
NO962167L (no) Deflektoranordning
DK0832553T3 (da) Mejetærsker
DE59710361D1 (de) Weichenendverschluss
NO965214L (no) Deflektor
DE69802853D1 (de) Schutzschalter
ATE235511T1 (de) Vielfältig verzweigte peptidkonstruktionen
DE69813938D1 (de) Schaltröhre
DE59703536D1 (de) Grenzwertschalter
KR970052895U (ko) 접지용 단자
DE59710772D1 (de) Leistungsschalter
NO965617D0 (no) Skillebryter
DK1017798T3 (da) Lunasinpeptider
NO20000976D0 (no) Peptider
SE9802536D0 (sv) Novel peptides
KR980005563U (ko) 접지용 단자

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees